“Many investors, especially more aggressive traders, look at lower-priced stocks as a way to not only make some good money but to get a higher share count,” points out the author of today’s article. For these more aggressive traders, he proceeds to highlight four biotech stocks that are currently trading under $10, offer solid upside potential, and have Buy ratings from Goldman Sachs. For the names and details of these four stocks, CLICK HERE.